Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2639-2649

  Yao, Virginia J ^a   Ozawa, Michael G ^a   Varner, Amanda S ^a   Kasman, Ian M ^a   Chanthery, Yvan H ^a   Pasqualini, Renata ^c   Arap, Wadih ^c   McDonald, Donald M ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG 013736; ALPHA1 BETA3 INTEGRIN; ANGIOGENESIS INHIBITOR; INTEGRIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; MALE; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ADENOMA, ISLET CELL; ANIMALS; BACTERIOPHAGE M13; ENDOTHELIAL CELLS; FEMALE; IMIDAZOLES; INDAZOLES; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; SUBSTRATE SPECIFICITY;

EID: 33645074410     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1824     Document Type: Article

References (49)

1. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 2002;8:563-71.
2. Risau W. Differentiation of endothelium. FASEB J 1995;9:926-33.
3. Gerber HP, Ferrara N. Angiogenesis and bone growth. Trends Cardiovasc Med 2000;10:223-8.
4. Lammert E, Cleaver O, Melton D. Induction of pancreatic differentiation by signals from blood vessels. Science 2001;294:564-7.
5. Matsumoto K, Yoshitomi H, Rossant J, Zaret KS. Liver organogenesis promoted by endothelial cells prior to vascular function. Science 2001;294:559-63.
6. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2:83-90.
7. v integrins during angiogenesis. Cancer J 2000;6 Suppl 3:S245-9.
8. v Integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-6.
9. 1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-62.
10. Marchiò S, Lahdenranta J, Schlingemann RO, et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004;5:151-62.
11. Kolonin MG, Pasqualini R, Arap W. Teratogenicity induced by targeting a placental immunoglobulin transporter. Proc Natl Acad Sci U S A 2002;99:13055-60.
12. Yao VJ, Ozawa MG, Trepel M, Arap W, McDonald DM, Pasqualini R. Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. Am J Pathol 2005;166:625-36.
13. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Bio/Technology 1995;13:265-70.
14. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999;5:1032-8.
15. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
16. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 2002;62:5139-43.
17. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004;112:496-507.
18. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1-17.
19. Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A 2002;99:7622-7.
20. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-40.
21. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
22. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8.
23. Wickman G, Hallin M, Dillon R, et al. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG013736, in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc Am Assoc Cancer Res 2003;44:A3780.
24. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
25. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52.
26. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
27. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
29. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-22.
30. Zacher AN III, Stock CA, Golden JW II, Smith GP. A new filamentous phage cloning vector: fd-tet. Gene 1980;9:127-40.
31. Smith GP, Scott JK. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol 1993;217:228-57.
32. Pasqualini R, Arap W, Rajotte D, Ruoslahti E. In vivo selection of phage display libraries. In: Barbas CF, III, Burton DR, Scott JK, Silverman GJ, editors. Phage display: a laboratory manual. Cold Spring Harbor (New York): Cold Spring Harbor Laboratory Press; 2001. p. 22.9.
33. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715.
34. 1 integrin on blood vessels in tumors. Am J Pathol 2005;167:193-211.
35. 1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res 2005;65:2712-21.
36. Byzova TV, Goldman CK, Pampori N, et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 2000;6:851-60.
37. 3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999;18:882-92.
38. 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp Cell Res 1996;224:39-51.
39. 1 integrins. Proc Natl Acad Sci U S A 1997;94:13612-7.
40. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-32.
41. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995;9:1760-70.
42. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:991-1006.
43. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
44. Ozawa MG, Yao VJ, Chanthery YH, et al. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer 2005;104:2104-15.
45. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228:1315-7.
46. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004;10:625-32.
47. Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor α as a candidate target in the progression of human prostate cancer. Cancer Res 2004;64:435-9.
48. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003;4:393-403.
49. Essler M, Ruoslahti E. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A 2002;99:2252-7.